Status:
COMPLETED
Spectro-IRM and Evaluation Response to Prostatic Radiotherapy
Lead Sponsor:
Centre Georges Francois Leclerc
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
Context: Prostate cancer is the most common non-cutaneous cancer and the second most common cause of cancer-related deaths in European and North-American men. After external radiotherapy or brachyth...
Eligibility Criteria
Inclusion
- Patients with a biopsy-proven prostatic adenocarcinoma
- Gleason score between 4 and 10
- Maximal baseline PSA \< 50 ng/ml
- Age over or = to 18 yr
- Exclusive radiotherapy and/or brachytherapy with or without androgen deprivation therapy
- Written informed consent from the patient
Exclusion
- lymph-node metastases
- Bone metastases
- Maximal baseline PSA ≥ 50 ng/ml
- Prior radical prostatectomy
- Contra-indications for MRI (Pace-maker, hip prothesis…)
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT01412853
Start Date
February 1 2008
End Date
December 1 2016
Last Update
June 21 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Georges François Leclerc
Dijon, France, 21000